← All Sponsors
SPONSOR

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Non-Small Cell Lung Cancer
NCT07182682 Phase 3
Recruiting

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Non-Small Cell Lung Cancer
China View Trial →